Related Experiment Video

Updated: Aug 9, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a

K S Rosenthal1, H Mao, W I Horne

  • 1N.E. Ohio Universities College of Medicine, Rootstown, 44272-0095, USA. ksr@neoucom.edu

Vaccine
|March 13, 1999
PubMed

Insights

A novel vaccine approach using a ligand epitope antigen presentation system (LEAPS) heteroconjugate demonstrated protection against viral challenge. This system primes a Th1-like immune response, crucial for vaccine efficacy.

Area of Science:

  • Immunology
  • Vaccinology
  • Molecular Biology

Background:

  • Cellular immunity relies on T-cell responses, particularly cytotoxic T lymphocytes (CTLs), for pathogen clearance.
  • Developing effective vaccines against viral infections requires strategies to elicit robust and protective T-cell mediated immunity.
  • Traditional vaccine approaches often struggle to effectively present CTL epitopes to the immune system.

Purpose of the Study:

  • To investigate the immunogenicity and protective capacity of a novel Ligand Epitope Antigen Presentation System (LEAPS) heteroconjugate vaccine.
  • To determine if the LEAPS heteroconjugate can elicit a protective T-cell response against viral challenge.
  • To explore the role of specific peptide sequences in enhancing CTL epitope presentation and immune response.

Main Methods:

  • Construction of a LEAPS heteroconjugate vaccine incorporating a CTL epitope (H1) from HSV-1 ICP27 and a beta-2-microglobulin peptide (J).
  • Evaluation of vaccine efficacy through intraperitoneal viral challenge and assessment of delayed-type hypersensitivity (DTH) responses.
  • Detection of anti-H1 peptide antibodies using ELISA following vaccination and natural infection.

Main Results:

  • The LEAPS heteroconjugate vaccine elicited significant protection against viral challenge and promoted DTH responses.
  • Unmodified H1 peptide or other heteroconjugates lacking the J peptide did not induce protection or DTH.
  • Antibodies to the H1 peptide were undetectable by ELISA, suggesting a T-cell mediated mechanism.
  • The LEAPS heteroconjugate appeared to prime a Th1-like immune response, boosted by subsequent infection.

Conclusions:

  • Attachment of the J peptide to a CTL epitope transforms it into an immunogenic vaccine component.
  • The LEAPS heteroconjugate strategy effectively promotes a protective Th1-type immune response.
  • This approach offers a promising strategy for developing vaccines that induce cellular immunity.

More Related Videos

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector08:10

Simultaneous Quantification of Anti-vector and Anti-transgene-Specific CD8+ T Cells Via MHC I Tetramer Staining After Vaccination with a Viral Vector

Published on: November 28, 2018

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Immune Response Against Viral Pathogens01:29

Immune Response Against Viral Pathogens

The immune system's response to viral infections is a complex and coordinated process involving natural killer (NK) cells, T cell-mediated responses, and antibody-mediated responses.
NK Cells
NK cells are a crucial part of our innate immune system, acting as the first line of defense against viral infections. These cells can recognize and kill infected cells without prior exposure to the virus, effectively slowing down the spread of infection. Additionally, NK cells produce proinflammatory...
Herpes01:28

Herpes

Herpes simplex type 1 (HSV‑1) is a widespread pathogen responsible for orolabial lesions. It is an enveloped, double-stranded DNA (dsDNA) virus belonging to the family Herpesviridae. Once the virus infects a host cell, its double‑stranded DNA genome is delivered into the nucleus, where a coordinated cascade of immediate‑early, early, and late gene expression directs viral DNA replication, structural protein synthesis, and virion assembly. After primary infection of epithelial cells, HSV-1...